ArticleFrontiers in cardiovascular medicine2026
Associations of Cholesin and GPR146 with atherosclerotic plaque stability: integrated bioinformatics and functional analyses.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerotic plaque instability is a major determinant of acute cardiovascular events; however, reliable blood-based indicators reflecting plaque stability remain limited. Cholesin, a recently identified endogenous ligand of G protein-coupled receptor 146 (GPR146), has been implicated in cholesterol metabolism, but its potential relevance to human atherosclerosis and plaque stability remains largely unknown. Methods: We used real-time quantitative PCR (RT-qPCR) to measure Cholesin expression in peripheral blood mononuclear cells (PBMCs) from 60 participants, including patients with stable plaques, patients with unstable plaques, and controls. Public transcriptomic datasets (GSE100927, GSE28829, and GSE163154) were analyzed to characterize the expression patterns of Cholesin and GPR146 across plaque development and instability. Differential expression, co-expression, and functional enrichment analyses were performed. Results: Cholesin mRNA expression in PBMCs was higher in patients with stable plaques than in those with unstable plaques. In contrast, Cholesin expression in plaque tissue was downregulated in atherosclerotic lesions compared with controls but did not differ significantly between disease stages or stable and unstable phenotypes. In the GSE28829 dataset, GPR146 expression was upregulated in advanced lesions, and in GSE163154, GPR146 expression was higher in unstable than in stable plaques. In THP-1 cells, oxLDL treatment increased GPR146 expression, whereas GPR146 silencing attenuated oxLDL-induced pro-inflammatory gene expression. Conclusion: PBMC Cholesin mRNA was associated with plaque phenotype, whereas plaque-tissue Cholesin did not distinguish lesion stage or stability. In contrast, GPR146 expression was higher in advanced and vulnerable plaques, and GPR146 silencing attenuated oxLDL-induced pro-inflammatory gene expression in THP-1 monocytes. These findings identify GPR146 as a candidate molecule associated with plaque progression and instability, although its causal role requires further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.